- Home
- IMPP vs INMB Comparison
IMPP vs INMB Comparison
Compare IMPP & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- INMB
- Stock Information
- Founded
- IMPP 1981
- INMB 2015
- Country
- IMPP Greece
- INMB United States
- Employees
- IMPP N/A
- INMB N/A
- Industry
- IMPP Marine Transportation
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- INMB Health Care
- Exchange
- IMPP Nasdaq
- INMB Nasdaq
- Market Cap
- IMPP 119.7M
- INMB 103.3M
- IPO Year
- IMPP N/A
- INMB 2019
- Fundamental
- Price
- IMPP $3.48
- INMB $4.96
- Analyst Decision
- IMPP
- INMB Strong Buy
- Analyst Count
- IMPP 0
- INMB 2
- Target Price
- IMPP N/A
- INMB $21.00
- AVG Volume (30 Days)
- IMPP 149.3K
- INMB 252.2K
- Earning Date
- IMPP 11-26-2024
- INMB 10-31-2024
- Dividend Yield
- IMPP N/A
- INMB N/A
- EPS Growth
- IMPP N/A
- INMB N/A
- EPS
- IMPP 1.69
- INMB N/A
- Revenue
- IMPP $147,505,660.00
- INMB $42,000.00
- Revenue This Year
- IMPP N/A
- INMB N/A
- Revenue Next Year
- IMPP $36.53
- INMB N/A
- P/E Ratio
- IMPP $2.06
- INMB N/A
- Revenue Growth
- IMPP N/A
- INMB N/A
- 52 Week Low
- IMPP $1.44
- INMB $4.78
- 52 Week High
- IMPP $4.59
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- IMPP 31.17
- INMB 36.75
- Support Level
- IMPP $3.42
- INMB $6.09
- Resistance Level
- IMPP $3.56
- INMB $6.26
- Average True Range (ATR)
- IMPP 0.09
- INMB 0.38
- MACD
- IMPP -0.01
- INMB -0.10
- Stochastic Oscillator
- IMPP 16.22
- INMB 2.57
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.